Nabriva Therapeutics plc Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nabriva Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2023.
  • Nabriva Therapeutics plc Operating Income (Loss) for the quarter ending June 30, 2023 was -$12M, a 15.6% decline year-over-year.
  • Nabriva Therapeutics plc Operating Income (Loss) for the twelve months ending June 30, 2023 was -$54M, a 18.3% decline year-over-year.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2022 was -$55.5M, a 14.3% decline from 2021.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2021 was -$48.5M, a 26.6% increase from 2020.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2020 was -$66.1M, a 16.8% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$54M -$12M -$1.63M -15.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-10-19
Q1 2023 -$52.4M -$8.48M +$3.08M +26.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-22
Q4 2022 -$55.5M -$22.3M -$9.45M -73.3% Oct 1, 2022 Dec 31, 2022 10-K 2023-04-17
Q3 2022 -$46M -$11.2M -$388K -3.59% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$45.7M -$10.4M +$983K +8.64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-19
Q1 2022 -$46.6M -$11.6M +$1.89M +14.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q4 2021 -$48.5M -$12.9M +$5.38M +29.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 -$53.9M -$10.8M +$2.4M +18.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$56.3M -$11.4M +$3.07M +21.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$59.4M -$13.4M +$6.74M +33.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$66.1M -$18.3M +$3.8M +17.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-04-17
Q3 2020 -$69.9M -$13.2M +$3.98M +23.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$73.9M -$14.5M +$6.52M +31.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$80.4M -$20.2M -$944K -4.91% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$79.5M -$22.1M +$8.81M +28.5% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$88.3M -$17.2M +$35.7M +67.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$124M -$21M -$3.27M -18.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$121M -$19.2M -$6.38M -49.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$114M -$30.9M -$8.6M -38.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$106M -$52.9M -$32.2M -155% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$73.6M -$17.7M -$2.15M -13.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$71.4M -$12.9M +$2.34M +15.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$73.8M -$22.3M -$7.54M -51.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$66.2M -$20.7M -$6.65M -47.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$59.6M -$15.6M -$4.04M -35% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$55.5M -$15.2M -$498K -3.39% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$55M -$14.7M -$4.5M -43.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$50.5M -$14.1M -$5.75M -69.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-16
Q2 2016 -$44.8M -$11.5M -$6.01M -109% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-16
Q1 2016 -$38.8M -$14.7M -$11M -301% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-16
Q4 2015 -$27.8M -$10.2M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$8.33M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-24
Q2 2015 -$5.52M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-24
Q1 2015 -$3.67M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.